Drug Information

Drug General Information
Drug ID
D0F3PU
Former ID
DCL000535
Drug Name
Iboctadekin + Doxil
Indication Ovarian cancer [ICD9: 183; ICD10:C56] Phase 1 [522292], [550972]
Company
GSK
PubChem Compound ID
5478883, 31703
Target and Pathway
Target(s) DNA topoisomerase II Target Info Inhibitor [550963]
Interleukin-18 Target Info Modulator [550963]
KEGG Pathway Cytokine-cytokine receptor interaction
NOD-like receptor signaling pathway
Cytosolic DNA-sensing pathway
Salmonella infection
Legionellosis
African trypanosomiasis
Malaria
Tuberculosis
Influenza A
Inflammatory bowel disease (IBD)
Rheumatoid arthritis
NetPath Pathway IL4 Signaling Pathway
PANTHER Pathway Interleukin signaling pathway
Toll receptor signaling pathway
Pathway Interaction Database IL27-mediated signaling events
IL12-mediated signaling events
IL23-mediated signaling events
Cellular roles of Anthrax toxin
IL12 signaling mediated by STAT4
Reactome Interleukin-1 processing
WikiPathways Hypertrophy Model
IL1 and megakaryotyces in obesity
Corticotropin-releasing hormone
NOD pathway
References
Ref 522292ClinicalTrials.gov (NCT00659178) Combination Study Of SB-485232 (Interleukin 18) And Doxil For Advanced Stage Epithelial Ovarian Cancer. U.S. National Institutes of Health.
Ref 550972Clinical pipeline report, company report or official report of GlaxoSmithKline.
Ref 550963Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Tang and Dr. Zhang.